Figure 3. SUMOs colocalize with familial ALS-linked SOD1 mutants in intracellular aggregates.
Image credit: Niikura, et. al. 2014 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Clinical FTD Research Pilot Grants
Sponsor: Association for FTD (AFTD)
Description: AFTD Clinical Research Pilot Grants provide seed funding for innovative research projects in the preliminary stages of development with the potential to address the unmet medical needs of frontotemporal degeneration (FTD). The FTD disorders include: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS/MND. Applications are welcome from investigators at not-for-profit institutions as well as for-profit organizations. The award is $60,000 USD for one year. Pilot Grant funded projects are intended to generate data to support follow-on grant applications to the National Institutes of Health (NIH) or other public or private agencies.
Deadline: Application due by September 8, 2017.



NEW! Pilot Grant for Basic Science FTD Research
Sponsor: The Association for FTD (AFTD)
Description: AFTD Basic Science Pilot Grants provide seed funding for innovative research projects that expand our understanding of the biology or pathophysiology of frontotemporal degeneration (FTD). The FTD disorders include: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS/MND. Applications are welcome from investigators at not-for- profit institutions or biotechnology startup organizations. The award is $60,000 USD for one year. Pilot Grant funded projects are intended to generate data that will support follow-on grant applications to the National Institutes of Health (NIH) or other public or private agencies.
Deadline: Application due by September 8, 2017.



Accelerating Drug Discovery for FTD
Sponsor: The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration
Description: This grant program seeks to accelerate and support innovative drug discovery programs for FTD. Funding priorities include (1)development and testing of novel high throughput screening assays; (2) identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies; (3) testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept; (4) development and/or characterization of new model organisms or cellular models to support drug discovery efforts. Award is $100,000-$150,000 for 1 year with the potential for renewal.
Deadline: Letter of Intent due by July 31, 2017.



NeuroNEXT Clinical Trials
Sponsor: National Institute of Neurological Disorders and Stroke
Description: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
Deadline: Application due by August 3, 2017.



Judith and Jean Pape Adams ALS Research Grants
Sponsor: The Judith and Jean Pape Adams Foundation
Description: These grants support research that is aimed at discovering the causes of and finding a cure for ALS. The Foundation funds research that is innovative and aggressive. The research must be of high scientific merit. We encourage partnerships and collaborative efforts in proposing initiatives to fill gaps not currently being investigated and that involve novel approaches. The foundation will begin receiving applications in March 2017.
Deadline: Application due by August 4, 2017.



Blueprint Neurotherapeutics Network
Sponsor: National Institutes of Health
Description: The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Deadline: Application due by August 9, 2017.



MND Research Grants
Sponsor: MND Australia
Description: Seed-funding for research that is innovative and has a clear relationship to the causes, treatments and cures of MND or the support of people living with MND. Applicants must have Australian permanent residency or be Australian citizens. Funding is up to $100,000 AUD for one year.
Deadline: Application due by August 25, 2017.



Postdoctoral Research Fellowships
Sponsor: MND Australia
Description: Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must have Australian permanent residency or be Australian citizens. Salary for a full-time research fellow will be funded at $100,000 p.a. for a period of up to three years.
Deadline: Application due by August 25, 2017.



The Betty Laidlaw MND Research Prize
Sponsor: MND Australia
Description: The Betty Laidlaw MND Research Prize aims to reward an outstanding mid-career researcher in Australia with a demonstrated background of excellence in neuroscience research. The Prize is for an innovative 12-month project to advance the understanding of classical MND with a clear potential for effective treatments. It aims to support research commencing in the calendar year 2018. Funding is up to $250,000 AUD for one year.
Deadline: Application due by August 25, 2017.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by September 30, 2017.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association. Applications received beginning September 8, 2017.
Deadline: Application due by November 3, 2017.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Healthcare Research Grants
Sponsor: Motor Neurone Disease Association (MNDA)
Description: MNDA invests in research that fills knowledge gaps in clinical management of MND, adding to the evidence base and driving improvements in quality of care for people affected by MND.  
Deadline: Now accepting applications.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail